Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression

SEBASTIEN TAURIN, KIRSTIE M. ALLEN, MARISSA J. SCANDLYN and RHONDA J. ROSENGREN

Department of Pharmacology and Toxicology, University of Otago, Adams Building, Dunedin 9016, New Zealand

Received April 21, 2013; Accepted June 3, 2013


Abstract. The poor prognosis of patients with triple-negative breast cancer (TNBC) and the lack of targeted treatments have raised the need for alternative therapies. Previous studies have suggested an effect of raloxifene, a selective estrogen receptor modulator that is independent of the estrogen receptor (ER). Therefore, we assessed the therapeutic value of raloxifene in TNBC mouse models. Mice received a daily oral treatment with different doses of raloxifene. Tumor progression was monitored weekly; in addition microvessel density, proliferation, migration and invasion, apoptosis and tumorigenicity were analyzed. This study demonstrates that raloxifene (0.85 mg/kg) prevents TNBC tumor growth and induces tumor regression. The treated tumors showed a 54% decreased microvascular density and proliferation and a 7-fold increase in apoptosis. The underlying therapeutic mechanism of raloxifene was associated with a 27-fold decrease in the expression of the epidermal growth factor receptor (EGFR). Moreover, raloxifene promoted the translocation of EGFR into endosomes associated with decreased cell migration, cell invasion and tumorigenicity in vitro. Together, these data showed that raloxifene acts independently of the ER and may be relevant for the treatment as well as control the progression of TNBC.

Introduction

Selective estrogen receptor modulators (SERMs) such as tamoxifen and raloxifene have proven to be successful in the treatment of breast cancer. Raloxifene, a second generation SERM, has been approved for the prevention of osteoporosis and the reduction of the risk of invasive breast cancer in postmenopausal women (1). In breast tissue, SERMs are thought to prevent proliferation of cancer cells by binding competitively to the estrogen receptor (ER) and blocking the mitogenic effect of estradiol (2). Although SERMs have a widespread clinical use, it is not established whether their therapeutic effects are solely mediated through the ER. Several studies have demonstrated that SERMs are effective against tumors that do not express ER such as lung cancer (3), brain cancer (4), melanoma (5) and breast cancer (6,7). Furthermore, SERMs have been demonstrated in vitro to trigger multiple signaling pathways that lead to ER-independent mediated cell death (reviewed in ref. 8).

Based on these earlier findings, we investigated the suppressive effects of raloxifene on triple-negative breast cancer (TNBC) growth. By definition, TNBC do not express ERα, progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2, ErbB2). They account for 10-17% of all breast cancers and represent 85% of the basal-like subtype (9). TNBCs generally have a higher prevalence in African-American women and an increased occurrence in premenopausal women (9). TNBCs are clinically aggressive and generally associated with a poor prognosis. Currently, chemotherapy remains the only systemic treatment option available for patients with TNBC (10).

In the present study, a daily oral dose of raloxifene not only suppressed tumor growth in two TNBC xenograft mouse models but also promoted tumor regression. The underlying therapeutic mechanism of raloxifene was associated with a decreased expression of EGFR which concurred with a decrease in cell proliferation, an increased incidence of apoptosis and a consequent decrease in blood vessels count within the tumors. In vitro experiments demonstrated that raloxifene decreased EGFR expression by promoting its endocytosis and translocation to small cytoplasmic vesicles akin to those of the endosomal pathway. In addition, raloxifene treatment reduced the migration, invasion and tumorigenicity of MDA-MB-231, a highly metastatic TNBC. Overall these data clearly showed that exploiting the ER-independent mechanisms of raloxifene can promote new therapeutic approaches against TNBC.

Materials and methods

Cell culture. MDA-MB-231, MDA-MB-468 and MCF-7 were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). The cells were grown in complete growth media composed of DMEM/Ham's F12 supplemented with 5% fetal bovine serum, 2 mM L-glutamine, 100 U/ml streptomycin, 100 U/ml penicillin and 2.2 g/l NaHCO₃.

Correspondence to: Dr Sebastien Taurin, Department of Pharmacology and Toxicology, University of Otago, Adams Building, 3rd floor, 18 Frederick Street, Dunedin 9016, New Zealand

E-mail: sebastien.taurin@otago.ac.nz

Key words: selective estrogen receptor modulator, raloxifene, breast cancer, estrogen receptor negative, epidermal growth factor receptor

Received April 21, 2013; Accepted June 3, 2013


Materials and methods

Cell culture. MDA-MB-231, MDA-MB-468 and MCF-7 were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). The cells were grown in complete growth media composed of DMEM/Ham's F12 supplemented with 5% fetal bovine serum, 2 mM L-glutamine, 100 U/ml streptomycin, 100 U/ml penicillin and 2.2 g/l NaHCO₃.
**Animals and treatments.** All animal protocols were approved by the University of Otago Animal Ethics Committee (91/07x2). Female CD1 athymic nude mice (5-6-week-old) were purchased from Hercus Taieri Resource Unit (Dunedin, New Zealand). Mice were inoculated subcutaneously into the right rear flank with triple-negative cells either MDA-MB-231 (2x10^6 cells/0.1 ml Matrigel) or MDA-MB-468 (8x10^6 cells/0.2 ml Matrigel). When tumors reached a size of ~100 mm^3 (MDA-MB-231 cells), 200 mm^3 (MDA-MB-468 cells) or 400-500 mm^3 (MDA-MB-468 cells for analyzing tumor regression), six animals were randomly assigned per treatment groups. Daily for 8-10 weeks as specified, mice received either raloxifene (0.5 mg/kg), raloxifene (0.85 mg/kg), raloxifene (12.5 mg/kg) or a vehicle control (0.25% DMSO). Two independent measurements of tumor volume (length x width x height) were performed weekly using electronic calipers.

**Western blot analysis, immunohistochemistry and indirect immunofluorescence.** Tissues and MDA-MB-468 cells were processed as described (11) and western blot analysis was performed either with EGFR antibody (Cell Signaling, Danvers, MA, USA), β-actin (Sigma-Aldrich, Auckland, New Zealand) or ERα (Abcam, Cambridge, MA, USA). Slides were incubated with the appropriate biotinylated secondary antibody either goat anti-α (BD Pharmingen) or goat anti-rabbit (Dako, Campbellfield, Australia). The sections were then incubated with streptavidin (BD Pharmingen) before development with 3,3'-diaminobenzidine tetrahydrochloride (DAB) (BD Pharmingen) and counterstained with hematoxylin QS (Vector Laboratories). In situ labeling of fragmented DNA, TUNEL assay (terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick-end labeling) was carried out using the apatog peroxidase *In Situ Apoptosis Detection kit* (Millipore, North Ryde, Australia) according to the manufacturer’s instructions. Indirect immunofluorescence microscopy was carried out as described previously (12). Briefly, cells were incubated with raloxifene for 48 h, fixed with 4% paraformaldehyde and incubated with EGFR antibody alone or in combination with EE1 or caveolin-1 antibodies (Cell Signalling). Secondary antibodies, conjugated to fluorescein or Texas Red (Dako), were used for co-localization. Nuclei were visualized using 4′,6-diamidino-2-phenylindole (DAPI) staining.

**Cell migration.** Migration of MDA-MB-231 cells was measured with the *in vitro* cell scratch assay. Confluent cells were scratched with a pipette tip and cellular debris were removed by extensive washing with serum-free medium. Raloxifene (10 µM) or DMSO as control was then added. Cells were allowed to migrate into the scrapped area for up to 20 h at 37°C and were captured at indicated intervals.

**Invasion assay.** MDA-MB-231 (5x10^6 cells/ml) were seeded onto growth factor-reduced Matrigel invasion chambers (8-µm pore; BD Biosciences) with or without raloxifene 10 µM for 20 h. Lower chambers contained DMEM/Ham's F12 supplemented with 5% FBS, a chemoattractant. Filters were fixed in methanol and stained using Diff-Quick staining solutions. Cells were counted from four fields of each well under an inverted microscope at magnification, x20. Their migration towards FBS was calculated as a percentage of the control. Data were collected from three independent experiments, each done in triplicate. Migrated cells were counted and the mean (± SE) between groups were analyzed using a Student’s t-test.

**Soft-agar assay.** The base layer consisted of 0.6% ultra-pure agarose (Invitrogen, Auckland, New Zealand) in DMEM/Ham's F12 supplemented with 5% FBS medium. Soft agar composed of 0.3% ultra-pure agarose in DMEM/Ham's F12 supplemented with 5% FBS medium was mixed with 15x10^5 MDA-MB-231 cells and plated on top of the solidified base layer in a 6-well-plate. Soft agar cultures were maintained at 37°C for an additional 21 days and treated with raloxifene at the indicated concentration (5, 10 or 15 µM) or DMSO (0.1%). Formed colonies were stained with 0.2% (w/v) crystal violet (Sigma-Aldrich) solution in 6% (v/v) paraformaldehyde solution (Sigma-Aldrich). Colonies were counted in images taken in four fields in each well. The assay was repeated three times with duplicate samples.

**Statistical analysis.** Before statistical analysis, data were log-transformed if parameters showed significantly different variances between control and treated mice (namely, tumor volume and tumor weight). Tumor growth experiments were analyzed using a repeated measures two-way ANOVA coupled with a Student-Newman-Keuls post hoc test, where *p*<0.05 is required for statistical significance. Analyses that were independent of time (i.e., tumor weight and protein expression) were analyzed using a one-way ANOVA coupled with a Student-Newman-Keuls post hoc test, where *p*<0.05 is required for statistical significance.

**Results**

A daily oral dose of raloxifene suppresses tumor growth. Tumor growth was abolished in two mouse models by a daily administration of raloxifene with optimal dose being 0.85 mg/kg (Fig. 1). In the first model, MDA-MB-231 xenograft tumors were seeded in mice until reaching a size of 100±12 mm^3. The doses of raloxifene used in this experiment were 25 and 15 times lower than the human equivalent dose of 60 mg when calculated based on body surface area (13). The results showed that after 4 weeks, the mice receiving raloxifene daily showed a significant reduction in tumor growth compared to vehicle control (Fig. 1A). At 8 weeks, these raloxifene treated groups showed tumors sized at ~100 mm^3, 10 times lower than those of the vehicle group (~1,000 mm^3) (*p*<0.001) and a similar size comparable to those before the start of the treatment. In the second model, the rear flanks of mice were implanted with MDA-MB-468 cells. The doses of raloxifene used were either 15 times lower or equivalent to the human dose of 60 mg. The results showed that after 10 weeks of treatment, tumor size for both raloxifene treated groups were three times lower than that of the vehicle treated group (450 mm^3) (*p*<0.001).
Changes in EGFR expression were observed in breast cancer cells in response to raloxifene treatment. Raloxifene reduced EGFR expression, which decreased the proliferation of cancer cells. This effect was more pronounced in TNBC cells, which are driven by EGFR signaling. Western blot analysis showed that raloxifene (0.85 mg/kg) significantly decreased the expression of EGFR protein (Fig. 3A and B). Treatment of MDA-MB-468 cells with raloxifene (10 µM) for 24 h in vitro also triggered a decreased expression of EGFR by >30% (data not shown). We confirmed that long-term in vivo raloxifene treatment did not induce ERα expression in MDA-MB-468 tumors (Fig. 3A). Raloxifene therapy significantly inhibited tumor cell proliferation, as shown by a 70% decrease in cells positive for Ki67 compared to vehicle controls (Fig. 3C). Moreover, raloxifene treatment induced an 8-fold elevation of the number of TUNEL-positive cells compared to the vehicle group (Fig. 3D and E).

**Raloxifene treatment promotes EGFR endocytosis.** Raloxifene treatment of MDA-MB-468 cells in vitro changes EGFR localization and promotes its transit towards small cytoplasmic vesicles. In untreated MDA-MB-468 cells, EGFR is highly expressed and localizes at the membrane but also shows a diffuse punctuate cytoplasmic staining (Fig. 4A). Whereas, after 48-h exposure to raloxifene (10 µM) triggers the accumulation of EGFR in small cytoplasmic vesicles (Fig. 4B). To establish the origin of the cytoplasmic vesicles containing EGFR, we probed two protein markers: early endosome antigen-1 (EEA1), which is essential for early endosome formation and trafficking (18) and caveolin-1, a marker of caveolae and endosome formation (19). In control cells, dual labeling with EEA1 and EGFR showed that these proteins colocalize within a few larger vesicles (Fig. 4B), while some vesicles contained caveolin-1 and EGFR antibodies colocalized both proteins (Fig. 4C). Western blot analysis of MDA-MB-468 cells showed that raloxifene treatment decreased EGFR phosphorylation and protein expression after a 24-h incubation and this was associated with a reduced expression of downstream effectors such as NFκB (Fig. 4E). Overall, these experiments show that the EGFR is internalized into cytoplasmic vesicles related to endosome formation. This suggests that the raloxifene mediated decrease in proliferation of cancer cells may be mediated through endocytosis of the EGFR which decreases proliferative signaling pathways.
Figure 2. A low oral dose of raloxifene causes TNBC regression in a xenograft model. Female athymic nude mice were implanted with MDA-MB-468 cells \((8 \times 10^6)\) and treated for 70 days with either vehicle \((\text{DMSO 0.25\%}, \text{p.o.})\) or raloxifene \((0.85 \text{ mg/kg}, \text{p.o.})\). (A) Tumor volume \((L \times W \times H)\) was measured weekly using electronic calipers. Symbols represent the mean ± SEM from 6 mice. Data were analyzed using a repeated measure two-way ANOVA coupled with the Student-Newman-Keuls post hoc test. The p-value was \(p<0.05\) after 5 weeks of treatment. (B) Tumor weight after 70 days of treatment with vehicle or raloxifene \((0.85 \text{ mg/kg}, \text{p.o.})\). Columns represent the mean ± SEM from 6 mice per group; † \(p<0.01\). (C) CD105 expression was assessed by immunohistochemistry of tissue sections obtained from tumors from both treatment groups as a representation of the mean vessel density. (D) The histogram shows the mean vessel density ± SEM from both groups; † \(p<0.05\).

Figure 3. Raloxifene treatment decreases EGFR expression, cell proliferation and induces apoptosis in TNBC xenograft tumors. (A) Representative western blots of EGFR and ERα protein expression in tumors. MCF-7 cell lysate was used as a positive control for ERα expression. (B) EGFR densitometry obtained from 6 mice from each treatment group. Data were analyzed using the Mann-Whitney U test in which \(p<0.05\) denoted a statistically significant difference. (C) Immunohistochemical staining of Ki67 in tissue sections of xenograft tumors obtained from vehicle and raloxifene treatment groups. Original magnification, x400. (D) TUNEL assay based immunohistochemical staining of apoptotic cells in tissue sections of xenograft tumor obtained from both treatment groups. Original magnification, x400. The arrows indicate positive TUNEL staining. (E) Quantification of apoptosis following TUNEL staining. Results are expressed as mean ± SEM of six 400X fields \((p<0.05)\).
Raloxifene decreases tumorigenicity, cell migration and cell invasion. Raloxifene treatment significantly decreased anchorage-independent growth of the highly metastatic MDA-MB-231 cells in soft agar. The assay we used represents an in vitro transformation phenotype that is highly correlated with in vivo tumorigenicity (20). Raloxifene not only dose-dependently suppressed colony formation of MDA-MB-231 cells (Fig. 5A and B) but treatment decreased their cell migration and invasion. Specifically, raloxifene (10 µM) reduced cell migration and delayed wound closure by 70% (Fig. 5C and D). The ability of raloxifene to prevent MDA-MB-231 cells to migrate and invade through Matrigel was then measured in
a transwell chamber. Raloxifene impaired invasion by >70% compared to control (Fig. 5E). Together these in vitro results provide further evidence that raloxifene significantly reduces the metastatic potential of TNBC cells.

Discussion

Despite the high rate of response to chemotherapy, patients presenting TNBC have considerably poor prognosis. This urges the development of novel targeted or combination therapies to reduce the mortality associated with these cancers. By identifying the targets and mechanisms behind the efficacy of a drug helps to carefully adapt treatment conditions to specific pathology of TNBC. The present study describes four major findings: i) a daily oral dose of raloxifene suppresses tumor growth in two xenograft mouse models of TNBC; ii) a daily oral dose of raloxifene promotes tumor regression in a xenograft model using MDA-MB-468 cells; iii) raloxifene treatment decreases the expression of EGFR and promotes its accumulation in endosomes; iv) raloxifene decreases tumorigenicity, cell migration and invasion of a highly invasive human TNBC cell line.

The efficacy of SERMs, tamoxifen and raloxifene, has been attributed to their ability to compete with 17β-estradiol antagonizing ER downstream signaling events (21). Several studies have demonstrated the in vivo and in vitro proapoptotic potential of SERMs in various ER-negative tissues and cells including bladder, glioma, melanoma or breast cancer (1,22-24). The in vitro effect of the SERMs was concentration-dependent, as growth arrest was induced by nanomolar concentrations while cell death was achieved in the micromolar range (1). In addition to the specific antagonistic effects of SERMs in the breast, other data suggest antitumorigenic effect of SERMs that are independent of ERα signaling. For example, raloxifene was shown to modulate phospholipase D activity (25) and more recently both raloxifene and tamoxifen were shown to reduce glutamine uptake (26).
In our study, we observed that raloxifene affects the expression of EGFR, a protein known to have a prominent role in the development of TNBC. EGFR expression is found in 45-70 of TNBC (27) and is a putative biomarker associated with an unfavorable prognosis (28). Analysis by western blot analysis showed that EGFR expression in tumors was decreased by a daily dose of raloxifene. The present study suggests that its effects on cell proliferation and apoptosis would stem from a decrease in EGFR and its clustering within endosomes. Furthermore, previous studies have demonstrated that internalized EGFR can promote caspase-3 mediated apoptosis (29).

Interestingly, SERMs such as raloxifene and tamoxifen were shown to bind with high affinity to the microsomal anti-estrogen binding site (AEBS) (30). AEBS is a protein complex composed of two enzymes and acts as a cholesterol epoxide hydrolase, an enzyme involved in cholesterol metabolism (31). AEBS has no affinity for estrogens and in the MDA-MB-468 cells, an ERα-negative breast cancer cell line, it is highly expressed in comparison to the ERα-positive cell line, MCF-7 (32). Recently, a study demonstrated that tamoxifen binding to AEBS induces the formation of small cytoplasmic vesicles or phagosomes in MCF-7 cells and their accumulation promoted cellular apoptosis (30). Few of these phagosomes contain the early endocytic marker EEA1 (33). These vesicles can fuse with endosomes leading to the degradation of their content (34). Moreover, caveolae vesicles have been shown to mediate the internalization of proteins at the plasma membrane into cells, such as the EGFR (35). Internalization of EGFR could follow two distinct endocytotic routes: the clathrin-dependent one and the clathrin-independent route mediated by caveolin (36). The EGFR-caveolin interaction reduces the activation of EGFR signaling (37). Furthermore, a recent study demonstrated that the accumulation of EGFR in the endosomes of MDA-MB-468 cells induced EGFR-mediated apoptosis (15).

However, the effects of raloxifene on EGFR expression and localization could be explained by another potential mechanism routed in the possible ability of ERβ to control EGFR signaling. Expression of ERβ has been detected in 20% of TNBC (38) and at lower level in MDA-MB-468 cells (39). However, its role, if any, in the development and progression of breast cancer remains unclear. Raloxifene binds with high affinity to ERα and ERβ and usually acts as an antagonist in the breast (40). Interestingly, a recent study has identified a physical interaction between ERβ, EGFR and caveolin-1 which reduces EGFR signaling in lung cancer (41), a similar mechanism involving raloxifene binding to ERβ and the triggering of EGFR endocytosis may be responsible for the tumor suppressing effect of raloxifene treatment in vivo and warrants further analysis.

Several studies have identified a truncated variant of ERα (ERα-36), which is frequently expressed in TNBC (42). ERα-36 has no intrinsic transcriptional activity (43) but mediates non-genomic estrogen signaling through the EGFR/Src/ERK signaling pathway in TNBC (44). ERα-36 was shown to possibly enhance tamoxifen agonist activity in endometrial cancer cell lines suggesting the capability of SERMs to directly bind to ERα-36 (45). Therefore, the effect of raloxifene could be mediated through ERα-36 interaction leading to a decreased EGFR expression and its downstream signaling pathways.

The majority of cancer-related deaths are caused by metastasis, a multistep process that depends on alterations of tumor microenvironment, survival of cancer cells in the circulation and colonization of a distant organ (46). Previous studies have shown that in TNBC, a low level of EGFR expression correlates with a reduced incidence of metastases (47). Inhibition of invasive potential is important for the prevention of tumor recurrence. Raloxifene treatment effectively reduced migration, invasion and the malignancy potential of MDA-MB-231 cells in vitro and reduced microvessel density in vivo. However, further in vivo studies are needed to definitively prove the potential of raloxifene alone or in combination to prevent ERα-negative metastasis.

Collectively these data show that an oral daily dose of raloxifene suppressed tumor growth in two relevant mouse xenograft models of TNBC. Moreover, raloxifene treatment acted independently of ERα and this was mediated by decreased EGFR protein levels and their altered localizations within endosomes. Overall, this study shows that raloxifene can be a valuable treatment for TNBC and significant new targets can be identified with further studies. This mechanistic information may lead to the development of new therapies for TNBC.

Acknowledgements

This study was supported by grants from the Otago Medical Research Foundation (AG302-ST), UORG (ST), Health Research Council of New Zealand (ST) and Lottery Health (ST). We would like to thank Ms. Hayley Nehoff and Ms. Céline Bourdon for the editorial assistance.

References


